CTI files appeal on FDA Decision on Pixantrone NDA
CTI had requested accelerated approval of its Pixantrone NDA for a patient group for which there are no drugs currently approved in this clinical setting. The Office of
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.